S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)

Enochian Biosciences Stock Forecast, Price & News

-0.10 (-1.72%)
(As of 01/14/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
220,695 shs
Average Volume
195,850 shs
Market Capitalization
$298.70 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive ENOB News and Ratings via Email

Sign-up to receive the latest news and ratings for Enochian Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Enochian Biosciences logo

About Enochian Biosciences

Enochian Biosciences, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. Its pipeline consists of ENOB-HV-01, ENOB- HV-11, ENOB-HV-12, ENOB-DB-01, ENOB-DC-01, ENOB-DC-11, and ENOB-DC-21. The company was founded by Rene Sindlev and Serhat Gumrukcu on January 18, 2011 and is headquartered in Los Angeles, CA.


Enochian Biosciences, Inc. (NASDAQ:ENOB) Short Interest Update
January 17, 2022 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
Book Value
$3.63 per share


Net Income
$-26.72 million
Pretax Margin




Free Float
Market Cap
$298.70 million
Not Optionable

Company Calendar

Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

0.33 out of 5 stars

Medical Sector

1358th out of 1,417 stocks

Pharmaceutical Preparations Industry

660th out of 683 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Enochian Biosciences (NASDAQ:ENOB) Frequently Asked Questions

How has Enochian Biosciences' stock price been impacted by Coronavirus (COVID-19)?

Enochian Biosciences' stock was trading at $2.25 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ENOB stock has increased by 154.2% and is now trading at $5.72.
View which stocks have been most impacted by COVID-19

Are investors shorting Enochian Biosciences?

Enochian Biosciences saw a increase in short interest during the month of December. As of December 31st, there was short interest totaling 1,580,000 shares, an increase of 46.3% from the December 15th total of 1,080,000 shares. Based on an average trading volume of 253,600 shares, the days-to-cover ratio is currently 6.2 days. Approximately 8.4% of the shares of the stock are sold short.
View Enochian Biosciences' Short Interest

When is Enochian Biosciences' next earnings date?

Enochian Biosciences is scheduled to release its next quarterly earnings announcement on Tuesday, February 15th 2022.
View our earnings forecast for Enochian Biosciences

Who are Enochian Biosciences' key executives?

Enochian Biosciences' management team includes the following people:
  • Mark Richard Dybul, Executive Vice Chairman & Chief Executive Officer
  • Luisa Puche, Chief Financial Officer
  • Joseph R. Cohen, Director-Research & Discovery

What other stocks do shareholders of Enochian Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Enochian Biosciences investors own include AcelRx Pharmaceuticals (ACRX), Aptinyx (APTX), Axcella Health (AXLA), Aytu Biopharma (AYTU), Calithera Biosciences (CALA), Cidara Therapeutics (CDTX), Catalyst Pharmaceuticals (CPRX), DURECT (DRRX), Geron (GERN) and LiveXLive Media (LIVX).

What is Enochian Biosciences' stock symbol?

Enochian Biosciences trades on the NASDAQ under the ticker symbol "ENOB."

Who are Enochian Biosciences' major shareholders?

Enochian Biosciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Wedbush Securities Inc. (0.02%).
View institutional ownership trends for Enochian Biosciences

Which institutional investors are buying Enochian Biosciences stock?

ENOB stock was purchased by a variety of institutional investors in the last quarter, including Wedbush Securities Inc..
View insider buying and selling activity for Enochian Biosciences
or or view top insider-buying stocks.

How do I buy shares of Enochian Biosciences?

Shares of ENOB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Enochian Biosciences' stock price today?

One share of ENOB stock can currently be purchased for approximately $5.72.

How much money does Enochian Biosciences make?

Enochian Biosciences has a market capitalization of $298.70 million.

How many employees does Enochian Biosciences have?

Enochian Biosciences employs 10 workers across the globe.

What is Enochian Biosciences' official website?

The official website for Enochian Biosciences is www.enochianbio.com.

Where are Enochian Biosciences' headquarters?

Enochian Biosciences is headquartered at 2080 Century Park EastSuite 906, Los Angeles CA, 90067.

How can I contact Enochian Biosciences?

Enochian Biosciences' mailing address is 2080 Century Park EastSuite 906, Los Angeles CA, 90067. The company can be reached via phone at (305) 918-1980 or via email at [email protected].

This page was last updated on 1/17/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.